| [1] |
Fouladiun M, Körner U, Bosaeus I, et al. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care--correlations with food intake, metabolism, exercise capacity, and hormones[J]. Cancer, 2005, 103(10): 2189-98. doi: 10.1002/(ISSN)1097-0142
|
| [2] |
David CJ, Chen M, Assanah M, et al. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer[J]. Nature, 2010, 463(7279): 364-8. doi: 10.1038/nature08697
|
| [3] |
Noguchi T, Yamada K, Inoue H, et al. The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters[J]. J Biol Chem, 1987, 262(29): 14366-71.
|
| [4] |
Noguchi T, Inoue H, Tanaka T. The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing[J]. J Biol Chem, 1986, 261(29): 13807-12.
|
| [5] |
Clower CV, Chatterjee D, Wang Z, et al. The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism[J]. Proc Natl Acad Sci U S A, 2010, 107(5): 1894-9. doi: 10.1073/pnas.0914845107
|
| [6] |
Mazurek S. Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells[J]. Int J Biochem Cell Biol, 2011, 43(7): 969-80. doi: 10.1016/j.biocel.2010.02.005
|
| [7] |
Bluemlein K, Grüning NM, Feichtinger RG, et al. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis[J]. Oncotarget, 2011, 2(5): 393-400. doi: 10.18632/oncotarget.v2i5
|
| [8] |
Mazurek S, Boschek CB, Hugo F, et al. Pyruvate kinase type M2 and its role in tumor growth and spreading[J]. Semin Cancer Biol, 2005, 15(4): 300-8. doi: 10.1016/j.semcancer.2005.04.009
|
| [9] |
Zhao H, Pflug BR, Lai X, et al. Metabolic and molecular regulation of dietary polyunsaturated fatty acids on prostate cancer[J]. Proteomics Clin Appl, 2016, 10(3): 267-79. doi: 10.1002/prca.v10.3
|
| [10] |
Hitosugi T, Kang SM, Heiden MG, et al. Tyrosine phosphorylation inhibits PKM2 to promote the warburg effect and tumor growth[J]. Sci Signal, 2009, 97(2): 73-8.
|
| [11] |
Gao X, Wang H, Yang JJ, et al. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase[J]. Mol Cell, 2012, 45(5): 598-609. doi: 10.1016/j.molcel.2012.01.001
|
| [12] |
Pfeiffer T, Bonhoeffer S. An evolutionary scenario for the transition to undifferentiated multicellularity[J]. Proc Natl Acad Sci USA, 2003, 100(3): 1095-8. doi: 10.1073/pnas.0335420100
|
| [13] |
Yu C, Xue J, Zhu W, et al. Warburg meets non-coding RNAs: the emerging role of ncRNA in regulating the glucose metabolism of cancer cells[J]. Tumour Biol, 2015, 36(1): 81-94. doi: 10.1007/s13277-014-2875-z
|
| [14] |
Vazquez A, Oltvai ZN. Molecular crowding defines a common origin for the Warburg effect in proliferating cells and the lactate threshold in muscle physiology[J]. PLoS One, 2011, 6(4): e19538-45. doi: 10.1371/journal.pone.0019538
|
| [15] |
Hussain A, Qazi AK, Mupparapu N, et al. Modulation of glycolysis and lipogenesis by novel PI3K selective molecule represses tumor angiogenesis and decreases colorectal cancer growth[J]. Cancer Lett, 2016, 374(2): 250-60. doi: 10.1016/j.canlet.2016.02.030
|
| [16] |
Xu Y, Liu XH, Saunders M, et al. Discovery of 3-(trifluoromethyl)-1H-pyrazole-5-carboxamide activators of the M2 isoform of pyruvate kinase (PKM2) [J]. Bioorg Med Chem Lett, 2014, 24(2): 515-9. doi: 10.1016/j.bmcl.2013.12.028
|
| [17] |
Dang CV. PKM2 tyrosine phosphorylation and glutamine metabolism signal a different view of the Warburg effect[J]. Sci Signal, 2009, 2(97): pe75-9.
|
| [18] |
Anastasiou D, Yu Y, Israelsen WJ, et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis[J]. Nat Chem Biol, 2012, 8(10): 839-47. doi: 10.1038/nchembio.1060
|
| [19] |
Christofk HR, Vander MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth[J]. Nature, 2008, 452(7184): 230-3. doi: 10.1038/nature06734
|
| [20] |
Fan J, Hitosugi T, Chung TW, et al. Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells[J]. Mol Cell Biol, 2011, 31(24): 4938-50. doi: 10.1128/MCB.06120-11
|
| [21] |
Spoden GA, Morandell D, Ehehalt D, et al. The SUMO-E3 ligase PIAS3 targets pyruvate kinase M2[J]. J Cell Biochem, 2009, 107(2): 293-302. doi: 10.1002/jcb.22125
|
| [22] |
Larsen A, Grudic A, Bjerkvig R, et al. Cell-cycle regulation and dynamics of cytoplasmic compartments containing the promyelocytic leukemia protein and nucleoporins[J]. J Cell Sci, 2009, 122(Pt 8): 1201-10.
|
| [23] |
Siwko S, Mochly RD. Use of a novel method to find substrates of protein kinase C delta identifies M2 pyruvate kinase[J]. Int J Biochem Cell Biol, 2007, 39(5): 978-87. doi: 10.1016/j.biocel.2007.01.018
|
| [24] |
Presek P, Glossmann H, Eigenbrodt E, et al. Similarities between a phosphoprotein (pp60src)-associated protein kinase of Rous sarcoma virus and a cyclic adenosine 3': 5'-monophosphate-independent protein kinase that phosphorylates pyruvate kinase type M2[J]. Cancer Res, 1980, 40(5): 1733-41.
|
| [25] |
Iqbal MA, Siddiqui FA, Gupta V, et al. Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2[J]. Mol Cancer, 2013, 12(8): 72-7.
|
| [26] |
Fukuda S, Miyata H, Miyazaki Y, et al. Pyruvate kinase M2 modulates esophageal squamous cell carcinoma chemotherapy response by regulating the pentose phosphate pathway[J]. Ann Surg Oncol, 2015, 22(Suppl 3): S1461-8.
|
| [27] |
Guo D, Gu J, Jiang H, et al. Inhibition of pyruvate kinase M2 by reactive Oxygen species contributes to the development of pulmonary arterial hypertension[J]. J Mol Cell Cardiol, 2016, 91(12): 179-87.
|
| [28] |
Lv L, Li D, Zhao D, et al. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth[J]. Mol Cell, 2011, 42(6): 719-30. doi: 10.1016/j.molcel.2011.04.025
|
| [29] |
Gao X, Wang H, Yang JJ, et al. Reciprocal regulation of protein kinase and pyruvate kinase activities of pyruvate kinase M2 by growth signals[J]. J Biol Chem, 2013, 288(22): 15971-9. doi: 10.1074/jbc.M112.448753
|
| [30] |
Zhao Y, Liu H, Liu Z, et al. Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism[J]. Cancer Res, 2011, 71(13): 4585-97. doi: 10.1158/0008-5472.CAN-11-0127
|
| [31] |
Vettraino M, Manerba M, Govoni M, et al. Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1[J]. Anticancer Drugs, 2013, 24(8): 862-70. doi: 10.1097/CAD.0b013e328363ae50
|
| [32] |
Wang HJ, Hsieh YJ, Cheng WC, et al. JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1α-mediated glucose metabolism[J]. Proc Natl Acad Sci USA, 2014, 111(1): 279-84. doi: 10.1073/pnas.1311249111
|
| [33] |
Fan FT, Shen CS, Tao L, et al. PKM2 regulates hepatocellular carcinoma cell epithelial-mesenchymal transition and migration upon EGFR activation[J]. Asian Pac J Cancer Prev, 2014, 15(5): 1961-70. doi: 10.7314/APJCP.2014.15.5.1961
|
| [34] |
Yang W, Xia Y, Ji H, et al. Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation[J]. Nature, 2011, 480(7375): 118-22.
|
| [35] |
Dong T, Yan Y, Chai H, et al. Pyruvate kinase M2 affects liver cancer cell behavior through up-regulation of HIF-1α and Bcl-xL in culture[J]. Biomed Pharmacother, 2015, 69(5): 277-84.
|
| [36] |
Mor I, Carlessi R, Ast T, et al. Death-associated protein kinase increases glycolytic rate through binding and activation of pyruvate kinase[J]. Oncogene, 2012, 31(6): 683-93. doi: 10.1038/onc.2011.264
|
| [37] |
Díaz JC, Moreira D, Sarandeses CS, et al. The M2-type isoenzyme of pyruvate kinase phosphorylates prothymosin α in proliferating lymphocytes[J]. Biochim Biophys Acta, 2011, 1814(2): 355-65. doi: 10.1016/j.bbapap.2010.10.004
|
| [38] |
Lu J, Tan M, Cai Q. The warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism[J]. Cancer Lett, 2015, 356(2 Pt A): 156-64.
|
| [39] |
Vander MG. Targeting cancer metabolism: a therapeutic window opens[J]. Nat Rev Drug Discov, 2011, 10(9): 671-84. doi: 10.1038/nrd3504
|
点击查看大图
下载:
